Business Express is an online portal that covers the latest developments in the world of business and finance. From startups and entrepreneurship to mergers and acquisitions, Business Express provides reporting on the stories that matter most to business leaders and decision-makers.The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
2024 04 03T102435Z 1 LYNXNPEK320E0 RTROPTP 4 USA HEALTH scaled - Business Express

Novo says Ozempic starter kits still not available in Germany in Q2

Novo says Ozempic starter kits still not available in Germany in Q2

By Ludwig Burger

FRANKFURT (Reuters) – Novo Nordisk has warned that starter kits of its popular diabetes drug Ozempic will still not be available in Germany during the second quarter, as shortages in Europe due to the drug’s slimming effect drag out. In a statement by Novo posted on the website of German healthcare regulator BfArM on Tuesday, Novo urged physicians to only issue prescriptions for patients already on the therapy.

The Danish drugmaker also reiterated that doctors should only prescribe Ozempic for its approved use in diabetes, saying that there were sufficient supplies of Wegovy, the obesity drug that is based on the same active ingredient.

Novo said in November last year that the supply situation for new patients seeking to initiate Ozempic therapy in Europe should improve in the first quarter.

Amid continued off-label prescriptions of cheaper option Ozempic for people seeking to lose weight, Novo said in the November statement it would ration starter kits of Ozempic in Europe and reduce supplies of another diabetes drug, Victoza, to prioritise producing Ozempic.

It warned at the time that intermittent Ozempic shortages are expected throughout 2024.

Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!

By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.

In its German statement posted on BfArM’s website, Novo said the Ozempic 0.25 mg starter strength will still not be available in Germany during the second quarter, with the 0.5 mg intermediate dose only available in limited volumes.

In a bid to manage side effects and get the body used to the gut-hormone drugs, both Ozempic and Wegovy are initially given at low starter doses and the concentration of active ingredient per injection is increased over months in a practice known as dose escalation.


(Reporting by Ludwig Burger, Editing by Rachel More and Chizu Nomiyama)


Recent Post: